The pitch, at least on paper, sounds almost too precise to be true: a biotech platform that can zero in on the exact protein fragments that make cancer cells different from healthy tissue—even when both express the same broader target. It's the kind of granular targeting that has tantalized oncology researchers for years, and now a Cambridge startup thinks it has cracked the code.
Stipple Bio surfaced from stealth mode this week with $100 million in fresh capital—a heavily oversubscribed Series A that reflects investor enthusiasm for what the company calls its "Pointillist" platform. The financing, closed on April 6, 2026, positions Stipple to push its lead antibody-drug conjugate into the clinic sometime in early 2027, assuming the science holds up under scrutiny.
For a company founded just four years ago, it's a notable show of confidence. Then again, the founder pedigree doesn't hurt.
A Syndicate of True Believers
RA Capital Management, a16z Bio+Health, and Nextech Invest co-led the round, joined by a roster of earlier backers including Emerson Collective Investments (managed by Yosemite), GV, LoLa Capital Partners, and GordonMD Global Investments. According to Stipple, the capital should carry the company through 2029—a runway that gives management breathing room to generate clinical proof points before worrying about the next fundraise.
Derek DiRocco, a partner at RA Capital, and Thilo Schroeder, managing partner at Nextech, took board seats as part of the deal. Vineeta Agarwala of a16z Bio+Health, who backed Stipple at the seed stage, remains on the board.
The financing fits a broader pattern emerging in early-stage biotech. As of late January, over 40% of seed and Series A capital had flowed into rounds exceeding $100 million, according to Crunchbase data cited by Fortune. Mega-rounds, it seems, are no longer reserved for late-stage plays.
The On-Target, Off-Tumor Dilemma
Stipple's core technology is built around what the industry euphemistically calls "on-target, off-tumor toxicity"—a persistent headache in oncology drug development. The problem arises when a cancer drug correctly binds to its intended protein target but causes collateral damage because that same protein shows up in healthy tissue.
Antibody-drug conjugates, or ADCs, are particularly susceptible. These engineered molecules deliver a potent cytotoxic payload directly to cancer cells by hitching a ride on tumor-targeting antibodies. When they work, they're remarkably effective. When they don't—or when they hit the wrong cells—patients pay the price in serious side effects.
Enter Stipple's Pointillist platform, which the company describes as a method for identifying epitopes: the precise three-dimensional surface features on a protein that antibodies actually recognize. The hypothesis is straightforward enough. If you can find an epitope that exists on tumor cells but not on healthy cells expressing the same protein, you might thread the needle between efficacy and safety.
Whether that holds true in human trials is, of course, the $100 million question.
STP-100 and the Road to Clinical Proof
The company's lead program, STP-100, pairs this epitope-level targeting approach with what Stipple describes as a "clinically validated linker-payload combination"—industry shorthand for well-understood chemistry designed to release the drug's toxic cargo once inside a cancer cell. The specific target remains undisclosed, though the company says it's using the funding to advance STP-100 into early-stage clinical studies by early next year.
Stipple also has additional discovery and preclinical programs in the pipeline, though details there are similarly scarce. The company frames its platform as "modality-agnostic," meaning the technology could theoretically extend beyond ADCs to other therapeutic formats, but for now, the focus is squarely on antibody-drug conjugates.
Perhaps that's wise. ADCs have proven notoriously difficult to develop, but when they succeed—think Enhertu or Trodelvy—the market rewards them handsomely.
Serial Founders Return to the Well
Stipple was founded in 2022 by Aaron Ring, an associate professor at Fred Hutchinson Cancer Center, and Aashish Manglik, an associate professor of pharmaceutical chemistry at UCSF. Ring is something of a serial entrepreneur in biotech circles, having previously launched Simcha Therapeutics, ALX Oncology, and Seranova Bio. Manglik, meanwhile, is a Bowes Biomedical Investigator known for his structural biology work on GPCRs—cell-surface receptors that remain one of drug discovery's most lucrative hunting grounds.
Jeff Landau, who joined as CEO, brings operational heft from his prior roles as chief business officer and head of strategy at CytomX Therapeutics, another company working on precision tumor targeting technologies.
The initial seed round, completed in 2022, brought in $11,975,000 from a16z Bio+Health, Emerson Collective Investments, and OMX, according to SEC filings. That was enough to get the science off the ground. This Series A is meant to prove it actually works.
The Standard Inflection Point
Now comes the hard part. Stipple has until 2029—at least in theory—to translate a compelling platform story into clinical-stage data that investors and partners can actually bet on. The epitope-targeting thesis is intellectually elegant, but oncology is littered with elegant ideas that failed to deliver meaningful therapeutic advantages.
The real test will arrive when STP-100 enters human trials and Stipple can demonstrate whether its precision approach translates into a genuinely improved therapeutic index: better efficacy, fewer side effects, or ideally both. Until then, it's a well-funded hypothesis with a blue-chip syndicate willing to wait for answers.
In biotech, that's often the best you can hope for.
